Literature DB >> 29512233

Screening recipients of increased risk donor organs: A multicenter retrospective study.

Michael G Ison1,2,3, Meenakshi M Rana4, Kyle D Brizendine5, Sonia Chimienti6, Jade Le7, Rosette Kfoury8, Parvin Mohazabnia9, Nicole Theodoropoulos6.   

Abstract

Organ Procurement & Transplantation Network policy requires post-transplant screening of recipients of organs from donors at increased risk for transmission of HIV, hepatitis B virus, and hepatitis C virus. Available data suggest that follow-up testing of recipients is not routinely conducted. Data on increased risk donors and recipients of their organs from 2008 to 2012 were retrospectively collected from 6 transplant centers after IRB approval. Descriptive statistics were performed. About 363 (60%) recipients were screened for transmission of HIV, HBV, and/or HCV at some time point; 257 (70.8%) within 90 days of transplant. The type of test used to screen for infection was variable with many recipients (25%-43%) screened with serology alone. Our results reveal that post-transplant screening for HIV, HBV, and HCV in recipients of increased risk donor organs did not universally occur and testing methods were variable.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990HIVzzm321990; PHS increased risk donors; hepatitis B; hepatitis C; organ recipients; screening

Mesh:

Year:  2018        PMID: 29512233     DOI: 10.1111/tid.12862

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  1 in total

1.  Factors associated with hepatitis C antibody seroconversion after transplantation of kidneys from hepatitis C infected donors to hepatitis C naïve recipients.

Authors:  Uchenna Agbim; Orsolya Cseprekal; Masahiko Yazawa; Manish Talwar; Vasanthi Balaraman; Anshul Bhalla; Pradeep S B Podila; Benedict Maliakkal; Satheesh Nair; James D Eason; Miklos Z Molnar
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.